ARS Pharma reports preliminary Q4 2024 neffy revenue of $6.5M, cash $314M

ARS Pharmaceuticals, Inc.

2024-FY EPS reported $0.08 revenue$89,149,000

Preliminary neffy net product revenue for Q4 2024 was approximately $6.5 million, total 2024 revenue $7.1 million since launch on Sept 23.
Cash, cash equivalents and short-term investments were $314.0 million as of Dec 31, 2024, sufficient for at least three years.
More than 14,500 neffy two-pack units delivered in Q4 2024; over 3,000 healthcare providers prescribed neffy to date.
Express Scripts added neffy to commercial formularies in Nov 2024; targeting over 80% commercial coverage by Q3 2025.
sNDA for neffy 1 mg (children 15-30 kg) has PDUFA date March 6, 2025; launch expected Q2 2025 if approved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.